RSS-Feed abonnieren
DOI: 10.1055/s-2007-985864
© Georg Thieme Verlag KG Stuttgart · New York
Methylphenidat-Retard-Präparate bei Kindern und Jugendlichen mit ADHs - eine Übersicht
Methylphenidate of Retard Forms in Children and Adolescents with ADHD - an OverviewPublikationsverlauf
Publikationsdatum:
21. Dezember 2007 (online)
Zusammenfassung
Zum jetzigen Zeitpunkt sind Stimulanzien das Mittel der Wahl zur pharmakologischen Behandlung einer Aufmerksamkeits-/Hyperaktivitätsstörung (ADHS). Sie sind indiziert, wenn verhaltenstherapeutische und psychoedukative Maßnahmen alleine nicht ausreichen. Die Wirkdauer von schnell freisetzenden Präparaten ist oft nicht ausreichend. Mittlerweile wurden verschiedene retardierte Methylphenidatpräparate entwickelt und auch für den deutschen Markt zugelassen. Der Artikel gibt eine Übersicht über die klinischen Studien zu Wirksamkeit, Wirkdauer und Nebenwirkungsprofil der in Deutschland erhältlichen Darreichungsformen von Stimulanzien. In der klinischen Anwendung sind die neuen Retard-Produkte wirkungsvolle Alternativen, da die kontinuierliche mehrstufige Freisetzung des Wirkstoffs über den Tag verteilt nach morgendlicher Einmalgabe Vorteile bietet. Allerdings müssen unerwünschte Arzneimittelwirkungen durch die verlängerte Wirkungsdauer genau beobachtet werden. Eine individuelle Anpassung an die jeweiligen Erfordernisse der verschiedenen tageszeitabhängigen Bedürfnisse der Kinder und Jugendlichen ist erforderlich. Möglicherweise kann eine Kombination mit unretardiertem MPH zu einer besseren Wirkungs-/Nebenwirkungsrelation führen.
Abstract
As yet, stimulants remain the preferred means of treating attention-deficit/hyperactivity disorder (ADHD) pharmacologically. They are indicated when measures based on behavioural therapy or psychoeducation alone are not sufficient. How-ever, the period of effectiveness of immediate release stimulants is often not satisfactory. A variety of retarded forms of methylphenidate have now been developed and approved for the German market. This paper presents an overview of clinical studies on effectiveness, period of effectiveness and the profile of side effects of different forms stimulants available in Germany. In clinical practice, the new retard products represent effective alternatives. There is an advantage in administering this drug in a once-daily single dose. At the same time, the side effects that are caused by an extended period of effectiveness have to be studied in detail. A more precise adaptation to the daily obligations and needs of children and adolescents is needed. Possibly, a combination with unretareded MPH might lead to a better effect/side-effect profile.
Schlüsselwörter
ADHS - Pharmakotherapie - Methylphenidat - Retardformen - Psychostimulanzien - Nebenwirkungen
Key words
ADHD - pharmacotherapy - methylphenidate - retarded forms of methylphenidate side effects
Literatur
- 1 American Academy of Pediatrics . Clinical Practice Guideline: Diagnosis and Evaluation of the Child With Attention-Deficit/Hyperactivity Disorder. Pediatrics. 2000; 105 1158-1170
-
2 American Psychiatric Association .
Diagnostic and Statistical Manual for Mental Disorders . 4th ed. Washington, DC 1994 - 3 Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E. Long-acting medications for the hyperkinetic disorders: A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006; 15 476-495
- 4 Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: Antisocial activities and drug use. Journal of Child Psychology and Psychiatry. 2004; 45 195-211
- 5 Baumgaertel A, Wolraich M, Dietrich M. Comparison of diagnostic criteria for attention deficit disorder in a German elementary school sample. J. Am. Acad. Child Adolesc Psychiatry. 1995; 34 629-638
-
6 Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie. et al. (Hrsg). Döpfner M, Lehmkuhl G. Hyperkinetische Störungen (F90).
Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter, 3.überarbeitete und erweiterte Auflage . Deutscher Ärzte-Verlag 2007 - 7 Döpfner M, Lehmkuhl G. Evidenzbasierte Therapie von Kindern und Jugendlichen mit ADHS. Prax Kinderpsychol Kinderpsychiatr. 2002; 51 419-440
- 8 Döpfner M, Gerber WD, Banaschewski T, Breuer D, Freisleder FJ, Gerber-von Muller G, Gunter M, Hassler F, Ose C, Rothenberger A, Schmeck K, Sinzig J, Stadler C, Uebel H, Lehmkuhl G. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry. 2004; 13 ((Suppl 1)) I93-101
-
9 Dillon A.
Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents . National Institute of Clinical Excellence, London 2006 - 10 Faraone SV, Wilens T. Does stimulant treatment lead to substance use disorders?. Journal of Clinical Psychiatry. 2003; 64 ((suppl 11)) 9-13
- 11 Gonzalez MA, Pentikis HS, Anderl N, Benedict MF, Cory HH De, Dirksen SJ, Hatch SJ. Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther. 2002; 40 175-184
- 12 Holtkamp K, Peters-Wallraf B, Wüller S, Pfäffle R, Herpertz-Dahlmann B. Case Report: Methylphenidate-related growth impairment. J Child Adolesc Psychopharm. 2002; 12 55-61
- 13 Jadad AR, Booker L, Gould M, Kakuma R, Boyle M, Cunningham CE, Kim M, Schachar R. The treatment of attention-deficit hyperactivity disorder: An annotated bibliography and critical appraisal of published systematic reviews and metaanalyses. Can J Psychiatr. 1999; 44 1025-1035
- 14 Janssen-Cilag GmbH.. , Fachinformation Concerta® 18 mg/36 mg/54 mg Retardtabletten. 41457 Neuss. http://www.janssen-cilag.de
- 15 Jerome L. Can methylphenidate facilitate sleep in children with attention deficit hyperactivity disorder?. J Child Adolesc Psychopharm. 2001; 11 109
- 16 Kent JD, Blader JC, Koplewicz HS, Abikoff H, Foley CA. Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. Pediatrics. 1995; 96 320-325
- 17 Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet. 1999; 37 457-470
- 18 King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R. , Methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children (commercial in confidence information removed) 2004; Centre for Reviews and Dissemination (CRD): http://www.nice.org.uk/pdf/ADHD_assessment_report.pdf
- 19 Lisska MC, Rivkees SA. Daily methylphenidate use slows growth of children: a community based study. J Pediatr Endocrinol Metab. 2003; 16 711-718
- 20 Lopez F, Silva R, Pestreich L, Muniz R. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs. 2003; 5 545-555
- 21 Mannuzza S, Klein R, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys grown up. Arch Gen Psychiatry. 1998; 155 493-498
- 22 Marchetti A, Magar R, Lau H, Murphy EL, Jensen PS, Conners CK, Findling R, Wineburg E, Carotenuto I, Einarson TR, Iskedjian M. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther. 2001; 23 1904-1921 , 39
- 23 Markowitz JS, Straughn AB, Patrick KS, Vane CL De, Pestreich L, Lee J, Wang Y, Muniz R. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet. 2003; 42 393-401
-
24 MEDICE Arzneimittel Pütter GmbH & Co.KG .FACHINFORMATION Medikinet retard 10 mg/20 mg/30 mg/40 mg. Kuhloweg 37, 58638 Iserlohn http://www.medice.de
- 25 MTA Cooperative Group . A 14-month randomized clinical trial of treatment strategies for attention deficit/hyperactivity disorder. Archives of General Psychiatry. 1999a; 56 1073-1086
- 26 MTA Cooperative Group . Moderators and mediators of treatment response for children with attentiondeficit/hyperactivity disorder. Archives of General Psychiatry. 1999b; 56 1088-1096
-
27 Novartis Pharmaceuticals Corp .
Ritalin LA (methylphenidate HCL) product monograph . East Hanover (NJ): Novartis Pharmaceuticals Corp 2002 - 28 Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD. Once a day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001; 107 E105
- 29 Pelham WE, Karen E, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and Pemoline. Pediatrics. 1990; 86 226-236
- 30 Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners CK, MacCracken JT, Swanson JM, Hughes CW, Llana ME, Lopez M, Toprac MG. The texas children's medication algorithm project: report of the texas consensus conference panel on medication treatment of childhood attention-deficit/hyperactivity disorder. Attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc Psychiatry. 2000; 39 908-927
- 31 Remschmidt H, Schmidt M, Poustka F. Multiaxial classification of child and adolescent psychiatric disorders. [In German: Multiaxiales Klassifikationsschema für psychische Störungen des Kindes- und Jugendalters nach ICD-10 und DSM.IV.] 4. überarbeitete und erweiterte Auflage, Bern 2001
- 32 Rupprecht T, Schellmoser S, Wagner M, Wenzel D, Topf HG. Aufmerksamkeitsdefizit-Hyperaktivitäts-Syndrom (ADHS). Monatsschr Kinderheilkd. 2005; 153 463-468
- 33 Sevecke K, Dittmann R, Lehmkuhl G, Döpfner M. Atomoxetinbehandlung von Kindern und Jugendlichen mit ADHS. Monatsschr Kinderheilkd. 2006; 154 894-902
- 34 Sinzig JK, Gontard A von. Absences as differential diagnosis in children with attention-deficit disorder. Klin Padiatr.. 2005; 217 230-233
-
35 SIGN (Scottish Intercoligiate Guidelines Networt) .
Attention deficit and hyperkinetic disorders in children and young people: a national clinical guideline . Vol. 52 Edinburgh 2001 -
36 SIGN (Scottish Intercoligiate Guidelines Networt) .
A guidelines developer's handbook . SIGN, Edinburgh 2004 - 37 Sonuga-Barke EJ, Swanson JM, Coghill D, Cory HH De, Hatch SJ. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry. 2004; 4 28
- 38 Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, Griffin S. Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the life cycle. J. Am. Acad. Child Adolesc Psychiatry. 1996; 35 409-432
- 39 Swanson J, Greenhill L, Pelham W, Wilens T, Wolraich M, Abikoff H, Atkins M, August G, Biederman J, Bukstein O, Conners CK, Efron L, Fiebelkorn K, Fried J, Hoffman M, Lambrecht L, Lerner M, Leventhal B, MacBurnett K, Morse E, Palumbo D, Pfiffner L, Stein M, Wigal SB, Winans E. Initiating Concerta TM (Oros_methylphenidate HCl) in children with attention-deficit hyperactivity disorder. J Clin Res. 2000; 3 59-76
- 40 Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics. 2004; 113 e206-e216
- 41 Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A. European clinical guidelines for hyperkinetic disorder - first upgrade. Eur Child Adolesc Psychiatry. 2004; 13 ((Suppl 1)) 17-30
- 42 Taylor E, Sergeant J, Doepfner M, Gunning B, Overmeyer S, Möbius H-J, Eisert H-G. Clinical guidelines for hyperkinetic disorder. Eur Child Adolesc Psychiatry. 1998; 7 184-200
-
43
UCB GmbH .
2006;
, Fachinformation. Equasym® Retard. Hüttenstraße 205, 50170 Kerpen.
- 44 Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse?. A meta-analytic review of the literature. Pediatrics. 2003; 111 179-185
- 45 Wilens T, Pelham W, Stein M, Conners KC, Abikoff H, Atkins M, August G, Greenhill L, MacBurnett K, Palumbo D, Swanson J, Wolraich M. ADHD treatment with once-daily OROS® methylphenidate: interim 12-month results from a long-term open-label study. J. Am. Acad. Child Adolesc Psychiatry. 2003; 42 424-433
- 46 Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, MacBurnett K, Bukstein O, August G. Randomized, controlled trial of oros methylphenidate once a day in children with attentiondeficit/hyperactivity disorder. Pediatrics. 2001; 108 883-892
Korrespondenzadresse
Dr. R. Pelz
Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit
Postfach 12 21 20
68072 Mannheim
Telefon: +49/621/1703 45 41
Fax: +49/621/1703 45 05
eMail: reta.pelz@zi-mannheim.de